Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA3 | P07451 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632701 | 1.00 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL29988843 | 1.00 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31632704 | 1.00 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31632748 | 1.00 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31632753 | 1.00 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31632726 | 1.00 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31632691 | 1.00 | LMNA (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31632717 | 0.99 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL31632702 | 0.94 | CA2 (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28829696 | 0.94 | LMNA (0.55) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20240190952-A1 | IL-18 Binding Protein (IL-18BP) and Antibodies for Treating Inflammatory Diseases | AB2 BIO SA (CH) | 2024-06-13 | — | — | US | disclosed |
| US-11926663-B2 | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases | AB2 BIO SA (CH) | 2024-03-12 | — | — | US | disclosed |
| US-11897942-B2 | Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies | Temple University—Of the Commonwealth System of Higher Education (US) | 2024-02-13 | — | — | US | disclosed |
| US-11820817-B2 | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases | AB2 BIO SA (CH) | 2023-11-21 | — | — | US | disclosed |
| WO-2023166206-A1 | IL-18 BINDING PROTEIN (IL-18BP) IN THE TREATMENT OF VEXAS | AB2 BIO SA (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-20230250164-A1 | IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases | AB2 BIO SA (CH) | 2023-08-10 | — | — | US | disclosed |
| EP-4185313-A1 | AVOIDING OR MINIMIZING SIDE-EFFECTS RELATED TO CAR-T-CELL THERAPY | AB2 Bio SA (CH) | 2023-05-31 | — | — | EP | disclosed |
| CN-116194131-A | Avoiding or minimizing side effects associated with CAR-T cell therapy | AB2生物股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115925928-A | IL-18 binding proteins (IL-18 BP) in inflammatory diseases | AB2生物股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-7198801-B2 | Formulations for transdermal or transmucosal application | ANTARES PHARMA IPL AG (CH) | 2007-04-03 | — | — | US | disclosed |
| WO-2007030434-A2 | TRANSDERMAL DRUG DELIVERY DEVICES CONTAINING O-DESMETHYL VENLAFAXINE (ODV) OR ITS SALTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030537-A1 | TOPICAL FORMULATIONS CONTAINING O-DESMETHYL VENLAFAXINE (ODV) OR ITS SALTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070053968-A1 | Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054964-A1 | Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its salts | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1648406-A2 | USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS | Antares Pharma IPL AG (CH) | 2006-04-26 | — | — | EP | disclosed |
| US-20040219197-A1 | Formulations for transdermal or transmucosal application | ANTARES PHARMA, IPL, AG (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040198706-A1 | Methods and formulations for transdermal or transmucosal application of active agents | ANTARES PHARMA, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004080413-A2 | USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS | ANTARES PHARMA IPL AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-5472946-A | Topical administration of lincomycin, clindamycin, erthromycin and iododeoxyuridine on skin or mucuous membranes | DISCOVERY THERAPEUTICS, INC. | 1995-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198706-A1 | Methods and formulations for transdermal or transmucosal application of active agents | SHBG, CYP17A1, NR5A1 | LMNA 3783/4885CA12 655/4885CA1 1696/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | LMNA 3441/4885CA12 1845/4885CA1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.